Apellis Pharmaceuticals, Inc. Logo

Apellis Pharmaceuticals, Inc.

Biopharmaceutical company developing therapies by targeting the complement cascade.

APLS | US

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
100 FIFTH AVENUE, 2451 WALTHAM

Description

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing therapies for a broad range of debilitating diseases by targeting the complement cascade. The company's scientific approach is centered on controlling C3, a central protein in this part of the immune system, to treat conditions driven by its overactivation. Apellis's development efforts are concentrated in the areas of ophthalmology, hematology, and nephrology. Its portfolio of approved medicines includes SYFOVRE® (pegcetacoplan injection) for the treatment of geographic atrophy (GA) and EMPAVELI® (pegcetacoplan) for other serious, complement-driven diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2026-01-09 19:48
PRIMARY DOCUMENT
English DOC 7.6 KB
2026-01-06 22:06
PRIMARY DOCUMENT
English DOC 6.7 KB
2026-01-05 22:42
PRIMARY DOCUMENT
English DOC 7.8 KB
2026-01-05 22:39
PRIMARY DOCUMENT
English DOC 7.3 KB
2026-01-05 22:38
PRIMARY DOCUMENT
English DOC 7.2 KB
2026-01-05 22:37
PRIMARY DOCUMENT
English DOC 7.3 KB
2026-01-05 22:36
PRIMARY DOCUMENT
English DOC 7.2 KB
2026-01-05 22:35
PRIMARY DOCUMENT
English DOC 7.2 KB
2026-01-05 22:34
PRIMARY DOCUMENT
English DOC 7.2 KB
2026-01-05 21:06 English DOC 7.0 KB
2025-12-18 22:06
PRIMARY DOCUMENT
English DOC 7.1 KB
2025-12-16 16:24 English DOC 7.2 KB
2025-11-18 16:05
PRIMARY DOCUMENT
English DOC 7.1 KB
2025-11-17 16:28 English DOC 7.2 KB
2025-11-14 21:45 English DOC 11.8 KB

Automate Your Workflow. Get a real-time feed of all Apellis Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Apellis Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Apellis Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
United States of America
ACHV
AC Immune SA Logo
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
United States of America
ACRV
Acticor Biotech Logo
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
United States of America
ACTU
AcuCort AB Logo
Develops user-friendly drug formulations for severe and acute allergic reactions.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
United States of America
ABOS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.